|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1445 New York Avenue, NW, #800 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 4/20/2016 11:36:34 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015).
Support S. 1406, the Saving Access to Compounded Medications for Special Needs Patients Act.
Support S. 2615, the Increasing Competition in Pharmaceuticals Act
Lobby members of Congress to join the Congressional Skin Cancer Caucus.
Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, intended to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription.
Lobby members of House and Senate to send letters of support to FDA regarding the agencys proposed rule to restrict indoor tanning for youth under 18.
Advocate members of Congress for oversight of implementation of Sunscreen Innovation Act.
Lobby Congress on issues related to telemedicine.
Support legislation to establish a federal standard for the provision of telemedicine (H.R. 691, the Telehealth Modernization Act).
Support S.2175, Department of Veterans Affairs Provider Equity Act.
Advocate for increased price transparency for drugs and tools to help lower costs.
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Support H.R. 6, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures
Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 17 Labor/HHS/Education Appropriations and FY 17 Agriculture Appropriations bills).
Support legislation to adjust discretionary spending caps for biomedical research (S. 318/H.R. 531, Accelerating Biomedical Research Act; S. 289, American Cures Act)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015).
Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015).
Advocate on issues related to waste, fraud and abuse in Medicare
Advocate for increased funding and reforms to Graduate Medical Education.
Lobby Congress on improvements to Health Information Technology implementation.
Lobby Congress in opposition to repeal of the in-office ancillary and physician services exception for anatomic pathology services.
Lobby Congress on issues related to telemedicine and Medicare reimbursement.
Advocate on use and availability of health care data.
Lobby in support of legislation to provide more flexibility in the Meaningful Use program (H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act)
Advocate for EHR interoperability and enhancements to the federal certification system for health information technology (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015 and S.2511, Improving Health Information Technology Act).
Lobby in support of legislation to require the Secretary of Health and Human Services to issue guidance on the application of the Common Rule to clinical data registries (H.R. 965, Facilitating Participation in Clinical Data Registries Act of 2015).
Support legislation to improve transparency and due process in the Medicare RAC audit and appeals process (H.R. 2568, Fair Medical Audits Act).
Support legislation to reduce Medicare fraud and improve access to Death Master File, S. 1073, the Stopping Improper Payments to Deceased People Act.
Advocate for improving disease management and care coordination for patients with chronic diseases
Support preservation of the In Offices Ancillary Services Exemption under Stark Law regarding physician self-referral; respond to request for comment regarding possible changes to Stark Law.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Advocate for legislation to enact medical liability reforms.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services.
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |